POC and LOC devices are portable diagnostic tools that offer accurate biomarker tests in real-time, away from traditional laboratory settings. They are critical because they enable rapid diagnosis and continuous monitoring, which can drastically reduce hospital admission rates and mortality for patients with chronic cardiovascular conditions.
Microfluidic technology is the dominant force in the market. It enables the creation of compact, rapid, and highly accurate testing systems that require significantly reduced sample and reagent volumes, making multi-marker cardiac testing both cost-effective and portable.
Proteomic testing currently leads the market by providing precision-based insights into complex protein expressions linked to early disease manifestation. Metabolomic testing is an emerging field that maps metabolites to help clinicians assess patient responses and optimize treatments; it is expected to grow rapidly due to its synergy with proteomic data.
North America holds the largest market share due to its advanced healthcare infrastructure and high adoption of decentralized diagnostic solutions. However, the Asia-Pacific region is expected to record the fastest growth, driven by increasing healthcare spending, modernization of diagnostic systems, and a rising incidence of cardiovascular diseases.
Key barriers include stringent regulatory scrutiny and compliance frameworks that lengthen development cycles. Additionally, high capital requirements for development and supply chain dependencies—particularly regarding semiconductors and specialized reagents—pose significant challenges to production scalability.
AI is identified as a major growth opportunity. It is being integrated into diagnostic platforms to accelerate interpretation accuracy and provide predictive insights in biomarker testing, which enhances prognostic assessments and therapeutic decision-making for physicians.
In January 2024, Roche Diagnostics expanded its NT-proBNP assay line for rapid screening. In March 2024, Abbott launched an improved i-STAT POC analyzer with integrated heart failure biomarker testing and enhanced data connectivity for remote monitoring.
The industry is beginning to adopt eco-friendly materials in device manufacturing. This shift toward sustainability in microfluidics is recognized as an attractive opportunity to reshape long-term manufacturing trends while meeting global environmental standards.
Key market players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, QuidelOrtho Corporation, Becton Dickinson and Company, Thermo Fisher Scientific, OPKO Health Inc., Randox Laboratories, and bioMérieux.
